Sanofi teams up with India to make cheap ARVs in S.Africa

French pharmaceutical giant Sanofi has signed a partnership with India's Hetero to manufacture cheap anti-HIV drugs in South Africa, the company said on Friday.

"The agreement with Hetero will allow Sanofi to produce (anti-retrovirals) locally and contribute to the government's objective to secure 80 percent locally supplied ARVs," said Christopher Viehbacher, chief executive of Sanofi.

Sanofi, which has seven in six , has recently upgraded its factory north of Pretoria in order to meet the increased production.

Other factories are located in Algeria, Tunisia, Morocco, Egypt and Senegal.

"There is a continuous supply shortage for critical medicines for HIV/AIDS. Only 50 percent of patients are able to receive treatment and there is a real need for more locally manufactured and supplied affordable ARVs," Viehbacher said in a statement.

South Africa has one of the world's highest infection rate, with 5.6 million people with HIV, in a population of 50 million.

The South African government's ARV programme is the largest in the world, serving 1.3 million people.

"This agreement follows the government's priority to secure supply and create local jobs while providing quality medicines at affordable prices," he said.

According to the company, 80 million euros ($106.8 million) have been invested in Africa over the last five years and another 120 million euros will be invested over the next five years.

add to favorites email to friend print save as pdf

Related Stories

South Africa unveils plan to halve HIV infections

Dec 01, 2011

President Jacob Zuma on Thursday unveiled a plan to halve the number of HIV infections over the next five years, cementing South Africa's turnaround from years of deadly denialism.

S. African to double HIV patient treatment

Dec 14, 2010

(AP) -- South Africa's health minister says he has brought down the cost of HIV drugs by 53 percent, enabling the government to treat twice as many patients in the next two years.

S.Africa conducts trials for shorter TB treatment

Mar 30, 2012

South African researchers said Friday they were conducting medical trials to shorten the duration of tuberculosis treatment to make it easier for patients to complete the full regimen.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

24 minutes ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments